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Urinary tract infections (UTIs) are the most common source of bacterial infections among young febrile children. Accurate
diagnosis of acute pyelonephritis (APN) and vesicoureteral reﬂux (VUR) is important because of their association with renal
scarring, leading in the cases to long-term complications. However, the gold standard examinations for both are either DMSA scan
(for APN and scar) or cystography (for VUR) and present limitations (feasibility, pain, cost, etc.). Procalcitonin, a reliable marker
of bacterial infections, was demonstrated to be a good predictor of both renal parenchymal involvement in the acute phase and
late renal scars. Furthermore, it was also found to be associated with high-grade VUR and was the key tool of a clinical decision
rule to predict high-grade VUR in children with a ﬁrst UTI. Therefore, procalcitonin may certainly be found playing a role in the
complex and still debated picture of which examination should be performed after UTI in children.
1.Introduction
Urinary tract infections (UTIs) are the most common source
of bacterial infections among young febrile children [1]; 7%
of girls and 2% of boys will have a UTI before 6 years of
age [2]. The nonspeciﬁc nature of symptoms among febrile
infants and young children renders the clinical diﬀerenti-
ation of upper and lower UTI diﬃcult. However, accurate
diagnosis and early treatment of acute pyelonephritis are
important because of its association with renal scarring [3].
Thus, the belief that future complications related to renal
scarring such as hypertension, pre-eclampsia, poor renal
growth, and end-stage renal failure can occur have been a
majordrivingforceintheimpetustoﬁrstmakeapromptand
high-quality diagnosis of UTI and then investigate the ﬁrst
occurrence of UTI for vesicoureteral reﬂux (VUR) and other
urinary tract abnormalities [4, 5]. But which examination
should be performed and in which order is a strongly
debated topic for both early UTI diagnosis examinations and
laterinvestigations[6–8].Amongthose,procalcitonin(PCT)
should ﬁnd a place in the diagnostic strategy for UTI. PCT,
a116-aminoacidpropeptideofcalcitoninwithouthormonal
activity, is a reliable marker of bacterial infections [9, 10]. In
this paper, we aimed to review the clinical interest of PCT,
and its place in the complex picture of which examination to
prescribe in children with UTI.
2.Procalcitonin
PCT is the prehormone of calcitonin, which is normally
secreted by the C cells of the thyroid in response to
hypercalcemia. Under normal conditions, negligible serum
PCT concentrations are detected [11], but PCT serum
level rises during bacterial infections, as ﬁrst demonstrated
by Assicot et al. [9]. The mechanism proposed for PCT
production after inﬂammation and its role are still not yet
completely elucidated. It is believed that PCT is produced
by the liver and peripheral blood mononuclear cells, mod-
ulated by lipopolysaccharides and sepsis-related cytokines.
Microbial infections induce a ubiquitous increase in CALC1
gene expression and a subsequent release of calcitonin2 Advances in Urology
precursors [12]. In bacterial infections, PCT increases from
concentrations in the picogram range (below the detection
level of current PCT assays) to plasma concentrations rang-
ing from 1 to 1000ng/mL. This increase often correlates with
the severity of diseases and with mortality [9]. Moreover,
PCT is very speciﬁc of bacterial infection and helps to
distinguish between viral and bacterial infections which is
particularly useful in children [10]. Increase in PCT occurs
more rapidly than increase in CRP. PCT can be detected in
the plasma 2 hours after the injection of endotoxins. Within
6–8 hours, PCT concentrations rise and a plateau is reached
after approximately 12 hours. PCT decreases to its normal
values after 2-3 days. This rapid and speciﬁc induction of
PCT after an adequate stimulus, and the high and reliable
production of PCT in patients with bacterial infections or
sepsis, suggests a pathophysiological function of PCT in the
acute immune response, even though it is not clear whether
PCT is a cytokine, a hormone, or an acute-phase protein
since it has characteristics of all these mediators.
PCT can be measured with a quantitative immunolu-
minometric assay (LUMItest PCT, progressively replaced by
PCT sensitive KRYPTOR, both from Brahms Diagnostica,
Berlin, Germany) in 2 hours, with a maximum interassay
variation of approximately 0.3ng/mL. A rapid semiquanti-
tative chromatographic test (Brahms PCT-Q, Brahms Diag-
nostica) can be used at the bedside and gives an indication of
PCT concentration (in bands of <0.5ng/mL, 0.5–2ng/mL,
2–10ng/mL, and >10ng/mL) in 30min.
PCT has been used for one and a half decades in a
number of hospitals as a clinical routine parameter for
the diagnosis of sepsis [13] since its ﬁrst demonstration
by Assicot et al. [9]. There are several reasons for the
clinical success of PCT. Plasma concentrations respond
rather speciﬁcally to bacterial infection, and PCT has been
demonstrated to be a better or at least of equal value
for diagnosis of sepsis when compared with markers like
CPR, lactate, proinﬂammatory cytokines, leukocytosis, and
fever [10]. Not only diagnosis of sepsis but also diagnosis
of speciﬁc infection can be improved by measuring PCT,
as demonstrated by the meta-analysis comparing PCT and
CRP in patients with bacterial versus viral or nonbacterial
infections [10]. Moreover, PCT is helpful in monitoring the
activity for the systemic inﬂammatory response, the success
of therapy, and in estimating prognosis [10, 13].
3. PCT and Acute Pyelonephritis
The nonspeciﬁc nature of symptoms of acute pyelonephri-
tis (APN) among febrile children renders the diagnosis
of upper UTI diﬃcult, whereas an accurate, quick, and
readily available diagnostic test for an early and high-quality
diagnosis of APN is of value. Renal scintigraphy with Tc-
99m dimercaptosuccinic acid (DMSA) is considered as the
gold standard for the demonstration of renal parenchymal
involvement in children with a UTI [14], once the diagnosis
of bacterial UTI remains indisputably based on the result of
urine culture [4, 5]. However, not only does this modality
entails irradiation, requires special equipment and facilities
for its completion that are not easily available in a number
of hospitals, but it is also expensive. Hence, a biological
marker that would assist the clinician into predicting renal
parenchymal involvement in a child with UTI would be
valuable. Several teams conducted cohort studies to inves-
tigate the diagnostic accuracy of PCT for APN (Table 1)
[15–27]. Most of authors concluded that PCT has a good
diagnosticaccuracyandaninterestingclinicalvalueforAPN,
with a sensitivity and a speciﬁcity ranging from 70 to 100%
and 70 to 97%, respectively, across studies and thresholds
[15–19, 21–27]. However, the Belgium team found lower
sensitivity and speciﬁcity (68% and 23%, resp.) with no
obvious diﬀerence regarding the cutoﬀ or the population’s
characteristics [20]. Mantadakis et al. summarised most of
these studies in a systematic review and meta-analysis (10
studies, n = 627) and demonstrated that the pooled diag-
nostic odds ratio (OR) measuring the association between
DMSA-proven APN and PCT was 14.3 (95% conﬁdence
interval—CI, 4.7–42.2), after having pooled results from
studies using close PCT threshold (0.5 and 0.6ng/mL) [28].
However, this pooled result may be questionable regarding
the strong heterogeneity it comes with (Q-test: P<. 001;
I2 = 80%). Interestingly, an updated meta-analysis validated
these results using individual patients data (17 studies, 13
centres, n = 1011); the relationship between APN and
PCT ≥0.5ng/mL after adjustment on all cofactors of interest
was signiﬁcant (adjusted OR = 6.4; 95% CI, 4.6–8.8), with
74% (95% CI, 71–78) sensitivity and 71% (95% CI, 66–75)
speciﬁcity [29]. This is encouraging in building algorithms
to identify children at high risk of acute pyelonephritis
(i.e., with proven renal parenchymal involvement) once the
diagnosis of UTI is made by urine culture in order to limit
early DMSA scan to them. However, pieces of evidence and
research are still needed before clinicians can use PCT as a
daily and perfectly deﬁned tool.
4.PCTandRenal Scarring
Beyondmakingaproper,high-quality,andpromptdiagnosis
of APN, the prediction of late renal scars is also of interest,
as it may be related to future complications, such as
hypertension, pre-eclampsia, poor renal growth, and end-
stage renal failure [30]. Pediatricians aim to early identifying
children with renal scars after UTI in order to propose a
more speciﬁc followup to prevent the impairment of the
renal function. The gold standard examination for scar is
DMSAscan6to12monthsafterUTI,andthesameproblems
of irradiation, availability, and cost make it not so often
performed. The PCT serum level at the time of UTI was
then studied by several authors as a potential predictor
for late renal scars (Table 2)[ 16–18, 20, 22, 26, 27, 31].
Zaﬀanello et al. reviewed these results in a nonsystematic
review and concluded to conﬂicting ﬁndings [32]. However,
a meta-analysis of the individual patient data (n = 361)
clariﬁed the discrepancies ﬁnding a signiﬁcant relationship
between renal scars and a PCT ≥0.5ng/mL (aOR = 2.1;
95% CI, 1.4–3.9) when pooling all the data together [29].
High PCT oﬀered a 79% (95% CI, 71–86) sensitivity andAdvances in Urology 3
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Table 3: Studies on prediction accuracy of procalcitonin for vesicoureteral reﬂux in children with urinary tract infection.
Study City, country n All-grade VUR High-grade VUR
aOR∗ Sensitivity Speciﬁcity OR Sensitivity Speciﬁcity
Prevur II study [34] Paris, France 136 4.9 (1.7–14.0) 85% (70–94) 44% (35–54) 8.7 (1.2–382) 92% (65–99) 44% (35–54)
Prevur III study [36] Multicentre 398 2.5 (1.4–4.4) 75% (66–83) 43% (37–48) 24.7 (1.5–415)† 100% (81–100) 43% (37–48)
Prevur IIIb study [37] Multicentre 526 — — — 2.5 (1.1–5.4)∗ 83% (71–91) 43% (38–47)
Prevur V study∗∗ [38] Multicentre 494 — — — 5.2 (2.4–11.3) 86% (74–93) 47% (42–51)
∗aOR: Adjustment on usual cofactors of interest: age, gender, family history, renal ultrasonography results, andurinecollection techniques (inPrevur IIIstudy
[36]), or early DMSA scan results (in Prevur IIIb study [37]).
∗∗This study built a rule combining PCT and ureteral dilation on renal ultrasonography and studied its prediction accuracy for high-grade VUR.
†Relationship between high PCT and grade 4 and 5 VUR.
All results were given with the 95% conﬁdence interval in brackets.
Abbreviations: aOR, adjusted odds ratio; VUR, vesicoureteral reﬂux.
a 41% (95% CI, 34–48) speciﬁcity [29]. Before clinical use
of PCT to identify children at high risk of renal scarring
afterUTIandselectivelyperformlateDMSA-scan,validation
studies and threshold analyses are needed to derive an
evidence-based clinical decision rule.
5.PCT andVUR
PCT has been demonstrated to be correlated to both APN
[28, 29] and late renal scars [29] on one hand, and on
another hand VUR is thought to be related to a higher
risk of APN and late renal scar [33]. PCT would thus be
of interest to also predict VUR in children with UTI and
could ﬁnd a place in the investigation strategy. A ﬁrst single-
centre study demonstrated a signiﬁcant relationship between
both all-grade and high-grade VUR and a PCT ≥0.5ng/mL
(aOR = 4.9; 95% CI, 1.7–14.0—Table 3)[ 34]. High PCT
sensitivities were 85% (95% CI, 70–94) and 92% (95%
CI, 65–99) for all-grade and high-grade reﬂux, respectively,
with 44% speciﬁcity (95% CI, 35–54) [34]. However, a
strong controversy was raised regarding the urine collection
techniquesused(sterilebags),suggestingthatthismighthave
overestimated results [35]. These results were conﬁrmed in
two multicentre studies, adjusting the relationship between
VUR and PCT on either urine collection techniques and
early DMSA scan results [36, 37]. Complex relationships
betweenUTI,renalparenchymalinvolvement,andVURmay
happen, and one can argue that PCT may only reﬂect the
presence of renal parenchymal involvement during UTI, and
by the way identify children with VUR as VUR is known
as a risk factor for acute pyelonephritis and renal scarring.
However, interestingly, the second European validation we
performed demonstrated that, in children with a proven
acute pyelonephritis, PCT is signiﬁcantly higher in children
with high-grade VUR (≥3) than in those with low-grade
or no VUR (1.5ng/mL, interquartile range: 0.5–4.0 versus
median 4.0ng/mL, inter-quartile range: 1.5–7.0, resp.; P<
.001). This deﬁnitively conﬁrmed that PCT is a reasonable
predictor for VUR. As recent publications demonstrated the
absence of beneﬁt for treating low-grade VUR, the target was
thenmorefocusedontheearlyidentiﬁcationofchildrenwith
only high-grade VUR. Finally, PCT was combined with renal
ultrasonography ﬁndings, in order to take into account that
clinicians believe in the high accuracy of ultrasonography,
and a clinical decision rule was derived and internally
validated[38].BasedonindirectrelationshipsbetweenVUR,
scar and PCT, and statistical work, we ended up with a
clinical tool combining PCT with renal ultrasonography that
may be useful for clinicians to predict high-grade VUR
in children with UTI and then selectively prescribe them
a cystography. The clinical decision rule proposed in its
current form that, for children aged 1 month to 4 years
with a ﬁrst febrile UTI, cystography should be performed in
cases with ureteral dilation (i.e., ureter visible whatever its
dilation) and a serum PCT level ≥0.17ng/mL, or without
ureteral dilatation (i.e., ureter not visible) when the serum
PCT level ≥0.63ng/mL. The rule had a sensitivity of 86%
(95% CI, 74–93) with a speciﬁcity of 47% (95% CI, 42–51).
The introduction of a renal ultrasonography criterion in the
decision rule may be arguable, as the diagnostic accuracy
of renal US for VUR is debated, with conﬂicting results in
literature [39]. However, this decision was made based on
the strong beliefs of pediatricians that renal US predicts well
VUR in order to derive a potentially well-accepted rule, and
the ultrasonographic criterion with the higher diagnostic
accuracy for VUR was chosen [40]. However, it needs an
external validation and a measure of its clinical impact,
as recommended in the standards for building such tools
[41, 42] before its daily and safe use in clinical practice.
6. Conclusion
PCT, a reliable marker of bacterial infections, would ﬁnd
a place in the complex and still debated picture of which
examination should be performed after UTI in children.
Indeed, PCT demonstrated a reasonable diagnostic accuracy
for both APN and renal scarring and has been proposed as
a key tool for a clinical decision rule to predict high-grade
VUR. However, more research is warranted to understand
more in depth the physiopathologic mechanisms of PCT
in bacterial infection and especially UTI on one hand,
and validations, threshold analyses, and impact studies are
required before daily and safe use of PCT on another hand.
Moreover, the exact place of this biomarker probably would6 Advances in Urology
need to be reﬁned when pediatrics societies would agree on a
diagram of the order and timing of investigations after UTI,
but PCT may be certainly found playing a role.
Abbreviations
APN: Acute pyelonephritis
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UTI: Urinary tract infection
VUR: Vesicoureteral reﬂux.
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